Ceftriaxone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ceftriaxone

Examples of brand names: Rocephin [DE]

ATC code: J01DD04

Main use (for orientation): Bacterial infections

Documented research summary

CBDV/ceftriaxone checkerboard experiment with 70 gonococcal isolates: median FICI 1.5, classified as indifferent; no established synergy. 575 isolates were tested for individual MICs, not all 575 in combination. No assurance of human tolerability or pharmacokinetic safety.

Uncertainties and limitations

The FICI finding is only an antimicrobial laboratory endpoint. Full text read at the publisher: doi 10.1128/spectrum.03952-22, methods/results/tables/limits of extrapolation. Missing data do not establish safety.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBDV – laboratory and animal studies

Finding ID: B0447

Type of result: Pharmacodynamics; null finding for synergy/antagonism under the FICI classification used

Observation: Median FICI 1.5 (range 0.75–3), assessed as indifferent; no synergy established.

Mechanism: Antimicrobial combination testing

Study type: In-vitro checkerboard test with gonococcal isolates

Context studied: Combination tested in 70 isolates (49 ceftriaxone-susceptible, 21 resistant). The 575 isolates belonged to the individual-MIC investigation, not the combination sample.

Clinical interpretation: Documented preclinical null finding, not general safety clearance.

Limitations and uncertainties: Bacterial laboratory endpoint, not a clinical tolerability or pharmacokinetic assessment. Cefixime comparison data are not evidence for a cefixime/CBDV combination.

Original sources for this finding: Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae. [VE_MED_36350125]

References and access status

[VE_LABEL_D0286] CEFTRIAXONE (CEFTRIAXONE SODIUM) INJECTION, SOLUTION [BAXTER HEALTHCARE COMPANY]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2024

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_36350125] Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae.

Original source / bibliographic reference

Authors: Yang F, Liu J, Gu Y, Jiao R, Yan J, Gao S, Lin X, van der Veen S.

Year: 2022

Source type: Research Support, Non-U.S. Gov't; research-article; Journal Article

DOI: 10.1128/spectrum.03952-22

PMID: 36350125

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility